Neurology News

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

TecTraum Inc. announced complete enrollment status for a clinical trial evaluating its pro2cool device, a noninvasive hypothermic therapy system for treating concussions.

PHILADELPHIA — An endovascular brain-computer interface allowed those who are paralyzed to perform computer-based activities, according to a presenter at the American Association of Neurological Surgeons annual meeting.

The Parkinson’s Foundation has expanded its PD GENEration study, a national initiative that offers no-cost genetic testing and counseling to those with Parkinson’s disease, to 23 actively enrolling participant sites.

Most patients with relapsing-remitting MS who are stable on natalizumab every 4 weeks, can switch to a 6-week dosing regimen without losing efficacy, according to results of a clinical trial published in the Lancet Neurology.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.

The FDA has issued a complete response letter to Axsome Therapeutics Inc., in which the agency declined to move forward with a new drug application for AXS-07, an acute treatment for migraine.

A computerized diagnostic tool was able to distinguish patients with normal cognition, mild cognitive impairment and dementia and may be useful in detecting early signs of cognitive impairment, according to a study published in JMIR Aging.

Pfizer revealed plans to open sites in the U.S. for a phase 3 study evaluating an investigational mini-dystrophin gene therapy in ambulatory patients with Duchenne muscular dystrophy.